ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Summary

ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.

Timeline

Start

2020-06-24

Primary completion

2024-07-15

Completion

2024-07-15

Drugs

Indications